Table 3 Relative risks of lung cancer in women using 1 to 2 or 15 or more aspirin tablets per week by duration of use and by latency period between aspirin assessment and lung cancer diagnosis

Abbreviations: P-Y=person–years; RRs=relative risks; CI=confidence intervals.
^aDuration was calculated as continuous years of aspirin use among current users.
^bP-Y of follow-up, in thousands, from 1980 to 2004.
^cRRs adjusted for age, smoking status, age at start of smoking (past and current smokers), years since quit smoking (past smokers), and cigarettes per day (current smokers).
^d95% CI.
^eP-value for linear trend over median values within categories of years of aspirin use.
^fDuring the latency periods for users of 1–2 aspirin tablets per week, women were censored if they reported ⩾15 tablets per week; during the latency periods for users of ⩾15 aspirin tablets per week, women were censored if they reported 1–2 tablets per week.
^gP-Y of follow-up, in thousands, through 2004 and beginning in 1980 for a latency of 0 to <2 years; in 1982 for a latency of 2 to <4 years; in 1984 for a latency of 4 to <6 years; and in 1986 for a latency of 6 to <8 years.
^hA latency of <2 years is the same as current users in Table 2 because aspirin use was assessed every 2 years.

Quick links

Search